Karsten Geletneky

Summary

Affiliation: German Cancer Research Center
Country: Germany

Publications

  1. pmc Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models
    Karsten Geletneky
    Department of Neurological Surgery, University of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany
    Neuro Oncol 12:804-14. 2010
  2. pmc Therapeutic implications of the enhanced short and long-term cytotoxicity of radiation treatment followed by oncolytic parvovirus H-1 infection in high-grade glioma cells
    Karsten Geletneky
    Department of Neurosurgery, University of Heidelberg, Heidelberg, Germany
    Bioeng Bugs 1:429-33. 2010
  3. pmc Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection
    Karsten Geletneky
    Department of Neurosurgery, University of Heidelberg, Heidelberg 69120, Germany
    J Biomed Biotechnol 2010:350748. 2010
  4. ncbi request reprint Parvovirus H-1 infection of human glioma cells leads to complete viral replication and efficient cell killing
    Marta Herrero Y Calle
    Department of Neurosurgery, University of Heidelberg, Heidelberg, Germany
    Int J Cancer 109:76-84. 2004
  5. pmc Bioavailability, biodistribution, and CNS toxicity of clinical-grade parvovirus H1 after intravenous and intracerebral injection in rats
    Karsten Geletneky
    Department of Neurosurgery, University Hospital, Heidelberg, Germany, Department of Applied Tumor Virology, German Cancer Research Center, Heidelberg, Germany
    Comp Med 65:36-45. 2015
  6. ncbi request reprint Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit
    Hans Herbert Steiner
    Department of Neurosurgery, University of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany
    J Clin Oncol 22:4272-81. 2004

Detail Information

Publications6

  1. pmc Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models
    Karsten Geletneky
    Department of Neurological Surgery, University of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany
    Neuro Oncol 12:804-14. 2010
    ..The results presented here and the innocuousness of H-1PV for humans argue for the use of H-1PV as a powerful means to perform oncolytic therapy of malignant gliomas...
  2. pmc Therapeutic implications of the enhanced short and long-term cytotoxicity of radiation treatment followed by oncolytic parvovirus H-1 infection in high-grade glioma cells
    Karsten Geletneky
    Department of Neurosurgery, University of Heidelberg, Heidelberg, Germany
    Bioeng Bugs 1:429-33. 2010
    ..A likely translation into current clinical treatment protocols is to use stereotactic radiation of non-resectable recurrent gliomas followed by intratumoral injection of H-1PV to harvest the synergistic effects of combination treatment...
  3. pmc Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection
    Karsten Geletneky
    Department of Neurosurgery, University of Heidelberg, Heidelberg 69120, Germany
    J Biomed Biotechnol 2010:350748. 2010
    ..To elucidate the influence of ionizing radiation (IR) on the oncolytic activity of Parvovirus H-1 (H-1PV) in human high-grade glioma cells...
  4. ncbi request reprint Parvovirus H-1 infection of human glioma cells leads to complete viral replication and efficient cell killing
    Marta Herrero Y Calle
    Department of Neurosurgery, University of Heidelberg, Heidelberg, Germany
    Int J Cancer 109:76-84. 2004
    ..These advantageous characteristics of H-1 virus infection of glioma cells, combined with the known low toxicity of H-1 virus in nontransformed cells, make parvovirus H-1 a promising candidate for oncolytic glioma therapy...
  5. pmc Bioavailability, biodistribution, and CNS toxicity of clinical-grade parvovirus H1 after intravenous and intracerebral injection in rats
    Karsten Geletneky
    Department of Neurosurgery, University Hospital, Heidelberg, Germany, Department of Applied Tumor Virology, German Cancer Research Center, Heidelberg, Germany
    Comp Med 65:36-45. 2015
    ....
  6. ncbi request reprint Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit
    Hans Herbert Steiner
    Department of Neurosurgery, University of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany
    J Clin Oncol 22:4272-81. 2004
    ..Also, we determined the influence on progression-free survival and overall survival and on vaccination-induced antitumor reactivity...